Role of Ormeloxifene in abnormal uterine bleeding

The efficacy and safety of ormeloxifene in medical management of abnormal uterine bleeding

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/12/016561

Enrollment

Registered

2018-12-07

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: N800- Endometriosis of uterus

Interventions

Intervention1: ORMELOXIFENE: ORMELOXIFENE IS A ASELECTIVE ESTROGEN RECEPTOR MODULATOR, GIVEN IN A DOSE OF 60 mg TWICE WEEKLY FOR 3 MONTHS Control Intervention1: NOT APPLICABLE : NOT APPLICABLE

Eligibility

Inclusion criteria

Inclusion criteria: ALL WOMEN IN REPRODUCTIVE AND PERIMENOPAUSAL AGE GROUP PRESENTING WITH AUB

Exclusion criteria

Exclusion criteria: women with bulky uterus presenting with pressure symptoms. submucosal fibroid endometrial hyperplasia and polyp, complex adnexal mass, acute aub requiring immediate surgical intervention, coagulopathy, systemic disease, history of breast malignancy.

Design outcomes

Primary

Measure	Time frame
PABC score to assess menstrual blood lossTimepoint: end of 3rd and 6th month	—

Secondary

Measure	Time frame
effect of dysmenorrhoes, menstrual periodicity, side effects, hemoglobinTimepoint: end of 3rd and 6th month	—

Countries

India

Contacts

Public ContactDr Krishma Thakur

gmch 32 chandigarh

bhartigoel14@gmail.com9646121606

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026